AIM
PRTK

Alambic Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Alambic Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,600
Closed -$82K – 368
2019
Q2 		$82K Buy
+20,600
New +$98K 0.05% 275

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Alambic Investment Management's PRTK Position: Q3 2019 in Review

Alambic Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2019, closing a stake of 20,600 shares — an estimated $82K sold.

Alambic Investment Management first reported a position in PRTK in Q2 2019 and held it in 1 quarter. The position peaked at $82K in Q2 2019. 91 funds tracked by Wall St. Rank hold PRTK as of Q3 2019.

  • Alambic Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Alambic Investment Management sold 20,600 Paratek Pharmaceuticals, Inc. shares in Q3 2019, an estimated $82K.
  • Alambic Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Alambic Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $82K in Q2 2019.
  • 91 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2019.

Based on Alambic Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.